UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Gene Therapy Studies

If you are interested in new approaches to possibly treat your HIV infection, the UCLA CARE Center's gene therapy studies may be an option for you.

Gene therapy involves removing some of your blood, changing some of the white blood cells (T-cells), and giving your blood back to you.


Calimmune CAL-USA-11

Currently enrolling HIV positive men and women, ages 18-65, who have been previously undetectable and no longer on treatment for at least 6 weeks prior to screening due to treatment fatigue, intolerance to HIV medications or no further improvements in cd4 counts. To participate, your CD4 count must be above 500 cells at screening and never below 250 cells, have a current viral load above 5,000 copies, not have a co-infection with Hepatitis B or C, have not received HIV vaccine or gene therapy, and have no steroid use, cancer diagnosis or chemotherapy for the last 5 years.

 What is the experimental treatment?

 Cal-1 is an experimental agent designed to remove a protein named CCR5 from your bone marrow and white blood cells. By reducing the level of CCR5, the researchers conducting this study have shown that HIV infection can be inhibited in those cells. Cal-1 is also designed to interfere with HIV infection in another way, by making a protein named C46 that has also been shown to block HIV infection.

 To add Cal-1 to your bone marrow and white blood cells, this study will use a delivery vehicle called a lentiviral vector. Once inside your white blood cells, the changes made by Cal-1 to those cells are permanent and together they may inhibit the ability of HIV to infect those cells and improve the immune system by allowing white blood cells to live longer (HIV usually kills the cells it infects).

For more information about the UCLA CARE Center's gene therapy studies, please contact:
Phone:  (310) 557-9062
Email:  CAREOutreach@mednet.ucla.edu